Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

Parkin, 2005, Global cancer statistics, 2002, CA Cancer J Clin, 55, 74, 10.3322/canjclin.55.2.74 Jemal, 2010, Cancer statistics, 2010 [published erratum appears in: CA Cancer J Clin 2011; 61:133-4], CA Cancer J Clin, 60, 277, 10.3322/caac.20073 2008, Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials, J Clin Oncol, 26, 4617, 10.1200/JCO.2008.17.7162 Caponi, 2010, Second-line treatment for non-small-cell lung cancer: one size does not fit all, Clin Lung Cancer, 11, 320, 10.3816/CLC.2010.n.040 Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753 Ciuleanu, 2012, Efficacy and safety of erlotinib versus chemotherapy in second-line, advanced, non-small-cell lung cancer (NSCLC) with poor prognosis: the phase 3 randomised Titan study, Lancet Oncol, 3, 300, 10.1016/S1470-2045(11)70385-0 Vamvakas, 2010, Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trial [Abstract], J Clin Oncol, 28, 7519, 10.1200/jco.2010.28.15_suppl.7519 Spigel, 2011, Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [Abstract], J Clin Oncol, 29, 7505, 10.1200/jco.2011.29.15_suppl.7505 Tsao, 1998, Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers, Lung Cancer, 20, 1, 10.1016/S0169-5002(98)00007-5 Masuya, 2004, The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients, Br J Cancer, 90, 1555, 10.1038/sj.bjc.6601718 Zucali, 2008, Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors, Ann Oncol, 19, 1605, 10.1093/annonc/mdn240 Birchmeier, 2003, Met, metastasis, motility and more, Nat Rev Mol Cell Biol, 4, 915, 10.1038/nrm1261 Merchant M, Zhang YW, Su Y, et al. Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; April 12-16; San Diego, CA, USA, 2008; Abstract 1336. Guo, 2008, Signaling networks assembled by oncogenic EGFR and c-Met, Proc Natl Acad Sci U S A, 105, 692, 10.1073/pnas.0707270105 Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Bean, 2007, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proc Natl Acad Sci U S A, 104, 20932, 10.1073/pnas.0710370104 Prat, 1998, Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF, J Cell Sci, 111, 237, 10.1242/jcs.111.2.237 Yu, 2011, Exploratory biomarker analyses from OAM4558g: a placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC) [Abstract], J Clin Oncol, 29, 7529, 10.1200/jco.2011.29.15_suppl.7529 Koeppen H, Januario T, Filvaroff E, et al. Characterization and clinical validation of an immunohistochemical assay for Met in non-small cell lung cancer. Proceedings of the 101st Annual Meeting of the United States and Canadian Academy of Pathology; March 17-23; Vancouver, BC, Canada, 2012; Abstract 2001. Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026